Pamela Lorditch
Nurse Practitioner · Johnstown, PANPI 1437146651
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,158 of the $81,233 with a category attached, or 74.1%. AbbVie accounts for 62.6% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $38,192 and has fallen 76.6% since, to $8,924 in 2025. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,167 payments — averaging $69.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$51K
- Biohaven Pharmaceuticals, Inc.$13K
- Teva Pharmaceuticals USA, Inc.$3K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
- UCB, Inc.$805
- Abbott$668
- plus $9K from 54 others
What the payments were for
- Speaking & faculty fees$60,15874%
- Travel & lodging$3,0304%
- Food & beverage$18,04222%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$44,413
- NURTEC ODT$15,761
- QULIPTA$14,962
- ZEPOSIA$363
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$146
- AUSTEDO$125
- Vumerity$125
- Trudhesa$113
- Proclaim IPG$107
- PROCLAIM$103
How this compares
$81,233 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 37 | $268,995 |
| Teriflunomide | 80 | $268,769 |
| RebifInterferon Beta-1a/Albumin | 24 | $230,506 |
| Austedo XrDeutetrabenazine | 29 | $229,699 |
| IngrezzaValbenazine Tosylate | 21 | $161,299 |
| FingolimodFingolimod Hcl | 30 | $112,286 |
| Nurtec OdtRimegepant Sulfate | 86 | $110,063 |
| Aimovig AutoinjectorErenumab-Aooe | 141 | $107,027 |
| Glatiramer Acetate | 26 | $81,823 |
| AptiomEslicarbazepine Acetate | 26 | $65,725 |
| QuliptaAtogepant | 50 | $58,914 |
| UbrelvyUbrogepant | 53 | $58,336 |
| Emgality PenGalcanezumab-Gnlm | 84 | $56,210 |
| VyeptiEptinezumab-Jjmr | 11 | $52,103 |
| BriviactBrivaracetam | 26 | $47,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $3,426 | $498,69466 claims |
| EMD Serono, Inc.Rebif | $229 | $230,50624 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $478 | $161,29921 claims |
| PfizerNurtec Odt, Dilantin | $211 | $118,752100 claims |
| AbbVieQulipta, Ubrelvy | $50,817 | $117,250103 claims |
| UCB, Inc.Briviact, Vimpat | $805 | $69,60952 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $109 | $65,72526 claims |
| Lundbeck LLCVyepti | $551 | $52,10311 claims |
| SK Life Science, Inc.Xcopri | $333 | $11,13511 claims |
| Amneal Pharmaceuticals LLCRytary | $360 | $8,93811 claims |
| Upsher-smith Laboratories LLCTopiramate | $41 | $4,596382 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Johnstown
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
- Faith MutalePhiladelphia$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.